Northern Gritstone is an investment firm focused on science and technology-enabled businesses in the North of England.
Northern Gritstone leads Series A round into the Manchester-based manufacturing technology platform.
"Northern Gritstone is delighted to support Partful. This growing Manchester-based tech company has already won large OEM customers thanks to its technology and is set to create more jobs in its North of England team"
Northern Gritstone led the over-subscribed seed round with participation from Empirical Ventures, Praetura Ventures, and private backers.
"Northern Gritstone is delighted to support Exciting Instruments’ internationally renowned team from the University of Sheffield. Their technology will open up a broad range of health-related research and discovery and will also support job creation in Sheffield’s thriving tech cluster."
Northern Gritstone led the seed extension round, which included participation from ACF Investors, Empirical Ventures, Deeptech Labs, and Hamamatsu Ventures.
"The progress made by the Silveray team since our initial investment in 2023 has been phenomenal. Dan Cathie and his team have the enviable combination of innovation and entrepreneurialism having developed a novel digital x-ray solution with numerous applications which are already disrupting the analogue x-ray market. We are delighted to continue our support of Silveray as it builds its commercial traction, helping the team on its path to success."
The equity round was led by EQT Life Sciences and Sectoral to support international expansion and clinical trials.
"Dysphagia is a severe medical condition that affects countless patients in hospital. It can increase hospital length of stay, the risk of complications, and lengthens recovery time. The Phagenyx System demonstrates significant reductions in hospital length of stay, with a corresponding and substantial reduction in healthcare costs, as evidenced by the Company’s strong portfolio of high-quality clinical studies. This is strongly aligned with EQT’s Health Economics strategy of transforming cutting-edge scientific innovation into impactful and cost-effective healthcare solutions. We‘re excited to support the next phase of Phagenesis’ journey."
Northern Gritstone and Parkwalk Advisors backed the seed round to support team expansion and product development.
"Medical devices follow a lengthy evaluation with a tiny amount of scientific evidence currently derived from computer modelling and simulation. The cost is ever-increasing, delaying lifesaving benefits to patients. Northern Gritstone’s and Parkwalk’s investment and support will enable adsilico to offer a scalable solution to the medical device market to produce evidence on an unprecedented scale"
